by The acute kidney injury treatment market is expected to grow exponentially owing to ongoing discoveries in prevention and management therapeutics. Acute kidney injury, also known as acute renal failure, is a common clinical syndrome characterized by a rapid decline in renal functions. Currently, there is no approved drug to treat established acute kidney injury. However, research is being conducted to develop novel therapeutics that target specific pathways in acute kidney injury’s pathophysiology.
The global acute kidney injury treatment market is estimated to be valued at US$ 1,857.8 million in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028).
Key Takeaways
Key players operating in the Acute Kidney Injury Treatment are Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co. Quark Pharmaceuticals Inc. is currently evaluating an investigational drug called QR-421a for the prevention of acute kidney injury. Baxter International and Fresenius Medical Care dominate the acute kidney injury management devices market with continuous renal replacement therapy devices.
The key opportunities in Acute Kidney Injury Treatment Market Demand include a rise in research funding for biomarker development and novel therapeutics. Biomarkers can help in the early detection of acute kidney injury and guide clinicians in differentiating intrinsic from prerenal causes. Several biotechs are working on therapies targeting inflammation, oxidative stress and apoptotic pathways to stop or slow acute kidney injury progression.
Advancements in artificial intelligence and machine learning are aiding the development of quick and affordable diagnostic tools for acute kidney injury. AI-powered tools can analyze a patient’s electronic health records and detect subtle changes indicating acute kidney injury earlier than conventional methods. This early detection enables timely intervention management strategies.
Market Drivers
The growing geriatric population is a major driver for the acute kidney injury treatment market. Older adults above 65 years of age have a higher risk of developing acute kidney injury due to age-related changes in kidney structure and function. Furthermore, the increasing prevalence of chronic illnesses such as diabetes and hypertension, which are prominent risk factors for acute kidney injury, will also propel market growth over the forecast period.
Challenges in Acute Kidney Injury Treatment Market
There are various challenges being faced currently in the acute kidney injury treatment market. One of the major challenges is lack of approved drug therapies. At present, there are no FDA approved therapies available in the market for acute kidney injury. Physicians usually rely on supportive care measures like renal replacement therapy. Developing novel and effective drug therapies poses significant challenges due to complex pathogenesis of acute kidney injury. Biomarkers useful for early detection of acute kidney injury are still under development which poses another challenge.
SWOT Analysis
Strength: Growing prevalence of acute kidney injury and increasing incidences of complications like sepsis and trauma leading to AKI.
Weakness: Lack of approved drug therapies and reliance on supportive care measures.
Opportunity: Significant unmet need, presents scope for development of novel therapeutics.
Threats: Complex pathogenesis of acute kidney injury makes drug development challenging. Strict regulatory requirements for approval of new drug entities pose another threat.
Geographical Regions
North America region currently dominates the Acute Kidney Injury Treatment Market Regional Analysis in terms of value and is expected to continue dominating during the forecast period. Presence of advanced healthcare infrastructure, growing geriatric population susceptible to AKI and high adoption of advanced renal replacement therapies are some factors responsible for its large market share.
Asia Pacific region is poised to be the fastest growing region during forecast period due to increasing healthcare expenditure, large patient pool suffering from diabetes and hypertension leading to kidney disorders, growing awareness about renal diseases. Countries like China and India will be major revenue generators for acute kidney injury treatment market in Asia Pacific.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
